[go: up one dir, main page]

CN1086142A - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN1086142A
CN1086142A CN93107990A CN93107990A CN1086142A CN 1086142 A CN1086142 A CN 1086142A CN 93107990 A CN93107990 A CN 93107990A CN 93107990 A CN93107990 A CN 93107990A CN 1086142 A CN1086142 A CN 1086142A
Authority
CN
China
Prior art keywords
antigen
vaccine
mpl
virus
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN93107990A
Other languages
English (en)
Other versions
CN1122530C (zh
Inventor
J·P·普里伊斯
N·M·-J·C·加康-约翰逊
M·施劳伊
P·帕拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9213559A external-priority patent/GB9213559D0/en
Priority claimed from GB929226283A external-priority patent/GB9226283D0/en
Priority claimed from GB939304056A external-priority patent/GB9304056D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1086142A publication Critical patent/CN1086142A/zh
Application granted granted Critical
Publication of CN1122530C publication Critical patent/CN1122530C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了包含3De-O-酰化的单磷酰类脂 A和QS21的疫苗组合物。该疫苗组合物是CTL和 γIFN应答的有效诱导物。

Description

本发明涉及新的疫苗制剂，其制备方法和其在医药上的应用。具体而言，本发明涉及包含QS21和3-De-O-酰化的单磷酰类脂A（3D-MPL）的疫苗，其中QS21为从Quillaja        Saponaria        Molina的茎皮得到的经高压液相色谱（Hplc）纯化的无毒成分。
3De-O-酰化的单磷酰类脂A可参见GB2，220，211（Ribi）。从化学上说，它是一种具有4、5或6酰化链的3-脱酰的单磷酰类酯A的混合物，是由Ribi    Immunochem        Montana制备的。
QS21是一种由南美树种        Ouillaja        Saponaria        molina的茎皮得到的皂苷经高压液相色谱（HpLe）纯化的无毒成分。其制备方法（以QA21）公开在US5，057，540中。
本发明是以下述惊人发现为基础的，即包含QS21和3D-MPL的组合体的制剂对于某种给定的抗原能协同增强免疫应答。
例如，疟疾抗原RTS，S佐以3D-MPL和QS21的疫苗制剂能有效地协同诱导脾脏中CS蛋白特异的细胞毒素的T淋巴细胞（CTL）的应答。
RTS是一种杂种蛋白，它包含有几乎所有的P.falciparum的环子孢子（CS）蛋白的C-末端部分，经乙肝表面抗原的preS2部分的四个氨基酸连接至乙肝病毒的表面（S）抗原上。其整体结构公开于审查中的国际专利申请PCT/EP92/02591中，以WO93/10152公开，优先权为UK专利申请号9124390.7。当以酵母表达时，RTS以脂蛋白颗粒产生，当其与来自HBV的S抗原一起表达时，产生一种称之为RTS，S的混合颗粒。
能够诱导强烈的溶细胞的T淋巴细胞应答的观测结果意义重大，因为在某些典型动物中这些应答已表现出可诱导对疾病的预防。
本发明人表明，两种佐剂QS21和3D-MPL与重组体颗粒抗原RTS，S的组合体能强有力地诱导脾脏中的CS蛋白特异性CTL.QS21自身也能增强诱导CTL，而3D-MPL则无此作用。可以说这种组合是以一种协同性的方式而起作用，这是因为，其效果大于每种佐剂单独的效果之和。这两种佐剂对CTL诱导的协同作用是一个惊人的发现，它有使用重组体分子作为用于诱导CTL介导的免疫的疫苗的重要结论。
当靶抗原在胞内合成时（如在病毒、胞内细菌的感染中，或在肿瘤中），易于发现CTL的诱导，这是因为由抗原的蛋白水解性分解产生的肽能够进入适宜的处理途径，从而导致与细胞膜上Ⅰ类分子有关的表现。但是，预形成的可溶性抗原通常不会到达该处理和表现途径，也不会诱出Ⅰ类约束的CTL。因而，传统的非活体疫苗在诱出抗体和T辅助应答时通常不能诱导CTL介导的免疫作用。两种佐剂QS21和3D-MPL的组合能够克服基于重组体蛋白的疫苗的这种严重的局限，且能诱导宽范围的免疫应答。
对CS蛋白的CTL特异性已表示出在小鼠模型体系中预防疟疾的功能（Romero等，Nature    341∶323（1989））。对人体进行实验时，使用辐照过的P.falciparum的子孢子使志愿者免疫，表明其可防止随后的疟疾进攻，因而显示出对CS表位特异性的CTL的诱导作用（Malik等Proc.Natl.Acad.Sci.USA.88∶3300（1991））。
由于根据免疫应答的产生和性能，使用辐照的子孢子将是不切实际的，因而诱导对于以重组体分子给药的抗原特异的CTL的能力与疟疾疫苗的开发是有关的。
除了疟疾疫苗，诱导CTL应答的能力还将有益于疫苗抵抗单纯疱疹病毒、细胞肥大病毒、人体免疫缺乏病毒，以及一般地病原体处于胞内生命期的所有病例。
同样，对于已知的肿瘤抗原特异的CTL也能通过一种重组体肿瘤抗原和两种佐剂的组合体进行诱导。这将有益于开发抗癌疫苗。
在一些体系中，3D-MPL和QS21的组合能协同增强干扰素γ的生成。本发明人通过利用称之为gD2t的单纯疱疹抗原表明了3D-MPL和QS21的协同作用潜力。gD2t是一种得自HSV-2的可溶性截断的糖蛋白D，并且可以按Berman等，Science 222 524-527所述的方法在CHO细胞中产生。
IFN-γ分泌与抗胞内病原体的保护性应答有关，所述病原体包括寄生物，细菌和病毒。由INF-γ活化巨噬细胞增强了微生物的胞内杀伤并增加了Fc受体的表达。直接的细胞溶解作用也可能发生，特别是与淋巴毒素（另一种THl细胞的产物）协同作用下发生。IFN-γ不仅是一种诱导物而且是NK细胞的一种产物，NK细胞为主要的先天保护效应物。或者通过IFN-γ或者通过其它机理实现的THI型应答优先有助于IgG2a免疫球蛋白同种型。
糖蛋白D位于病毒被膜上，也能在感染的细胞的细胞质上发现（Eisenberg R.J.等J.Of Virol 1980 35 428-435）。它含有393种包括一种信号肽的氨基酸，其分子量大约为60KD。在所有的HSV被膜糖蛋白中，这可能是最好的特征（Cohen等 J.Virology 60 157-166）。在体内公知它在病毒向细胞膜的附着中起中心作用。进而，糖蛋白D还表明能诱出体内中和抗体（Eing等 J.Med Virology 127∶59-65）。然而，潜伏的HSV2病毒仍然能被再活化并诱导疾病复发，尽管在患者的血清中存在高的中和抗体值。因而很明显，单独诱导中和抗体的能力并不足以适宜地控制疾病。
为了防止疾病复发，任何一种疫苗均需要不仅激发中和抗体，而且要激发通过T细胞特别是细胞毒性T细胞介导的细胞免疫。
在这种情况下，gD2l是308种氨基酸的HSV2糖蛋白D，所述氨基酸包括1至306天然存在的糖蛋白以及在截断蛋白的C末端处的天冬酰胺和谷氨酰胺。这种形式的蛋白包括信号肽，该肽被分成一种成熟的283氨基酸蛋白，在中国大田鼠（Chinese Hamster）的卵巢细胞中这种蛋白的生成在Genentech的EP-B-139417中有述。
从哺乳动物细胞中分泌出的成熟的截断糖蛋白D（rgD2t）或等价的蛋白是在本发明的疫苗制剂中优选使用的。
本发明的制剂能非常有效地诱导天竹鼠的生殖器疱疹模型中的保护免疫。即使采用非常低的抗原剂量（如低至5μg rgD2t），该制剂也能防止天竺鼠的原发感染且能促进特异性中和抗体应答。本发明人采用本发明的制剂已经表明了小鼠中效应物细胞介导的THI型应答。
相应地，本发明提供一种包含有一种抗原及3脱酰单磷酰类酯A和QS21的疫苗或药物制剂。该种制剂可适用于宽范围的单价或多价疫苗。
疫苗制剂最好包含一种抗原或抗原组合物，这种抗原或抗原组合物能够激发对人体或动物病原体的免疫应答，所述抗原或抗原组合物得自于：HIV-1（如gp120或gp160）、任一种猫免疫缺乏病毒、人或动物疱疹病毒如gD或其衍生物或Immediate    Early蛋白如由HSV1或HSV2得到的IGP27，细胞肥大病毒（特别是人的）如（gB或其衍生物）、Varicella    Zoster    Virus（水痘带状疱疹病毒）（如gPⅠ、Ⅱ或Ⅲ），或者得自于：肝类病毒如乙肝病毒如乙型肝炎表面抗原或其衍生物，肝类A病毒、肝炎C病毒和肝炎E病毒，或者得自于其它病毒病原体，如呼吸合胞体病毒、人类乳头状瘤病毒或流感病毒，或者得自于细菌性病原体如Salmonella（沙门氏菌）、Neisseria（奈瑟菌属）、Borrelia（疏螺旋体属）（如OspA或OspB或其衍生物）或Chlamydia（衣原体属）或Bordetella（博氏杆菌属）如P.69，PT和FHA，或者得自于寄生物如疟原虫或Toxoplasma（弓浆虫属）。
制剂还可以包含一种抗肿瘤抗原并用于免疫疗法治疗癌症。
制剂也可以用于与疱疹性轻颗粒一起使用，这些颗粒在国际专利申请PCT/GB92/00824和PCT/GB92/00179中有述。
乙型肝炎表面抗原衍生物在本领域中是公知的，它们包括在EP-A-414374;EP-A-0304578和EP198474中所述的PreS1，PreS2S抗原。
本发明的另一方面是提供了一种如下所述用于药物的疫苗。
QS21与3D-MPL的比值通常在1∶10～10∶1的数量级，优选1∶5～5∶1，更经常的是1∶1。为了最适宜的协同作用优选的范围是2.5∶1～1∶1    3DMPL∶QS21。对于人体给药，典型地在疫苗中每一个剂量中含QS21和3DMPL1μg～100μg，优选10μg-50μg。通常疫苗无需任何特殊的载体，它们能在水或其它药物可接受的缓冲液中配制。在有些情况下，本发明的疫苗最好还包含有明矾，或者是存在于水包油乳液中或其它适宜的载体中，如脂质体、微球体或包囊的抗原颗粒。
疫苗制剂通常描述在下述文献中：New    Trends        and        Developments        in        Vaccines，由Voller等编辑，University    Park        Press，    Baltimore，        Maryland，U.S.A.1978。在脂质体内的包囊也有述，如Fullerton的US4，235，877。蛋白与大分子的结合也有述，如Likhite的US4，372，945和Armor等的US4，474，757。
在每一疫苗剂量中蛋白的量应使其能诱导免疫保护应答但不会在典型的疫苗中造成显著且有害的副作用。这样的用量根据具体所采用的免疫原和它是如何存在的而改变。一般说来，最好每一剂量包含1-1000μg的蛋白，优选2-100μg，最优选4-40μg。对于特定的疫苗来说，其最适宜的用量可通过标准研究方法进行确定，该方法包括对主体观察其适宜的免疫应答。在开始接种后，主体可以接受一次或几次适当间隔的加强免疫接种。
本发明的制剂可用于预防和治疗。
相应地，本发明的另一个方面是提供一种治疗方法，包括对患者施用有效量的本发明的疫苗。
实施例
1.0        对诱导干扰素γ分泌的3D    MPL和QS21之间的协同作用
为了测定3D MPL和QS21为佐剂的含rgD2t的制剂诱导效应物细胞介导的免疫应答的能力，对几组Balb/c小鼠进行接种，按下述过程对其排液淋巴结细胞的IFN-γ分泌作用进行测试。
1.1 rgD2t制剂
该实验对三种佐剂的制剂进行比较：
ⅰ）在3D-MPL中的rgD2t
ⅱ）在QS21中的rgD2t
ⅲ）在3D-MPL/QS21中rgD2t
这些制剂制备过程如下：由CHO细胞产生rgD2t且相应于成熟的HSV-2gD的1-283氨基酸，按照Berman（Supra）的方法和EP0139417产生。
＊rgD2t/3D-MPL
在搅拌，室温下将5μg rgD2l/剂量培养1小时，然后与3D-MPL悬浮液（25μg/剂量）混合。用氯化钠溶液（5M，PH6.5±0.5）和注射用水调节体积至70μl/剂量得到最后的浓度为0.15M NaCl。PH保持在6.5±0.5。
＊rgD2l/QS21
在搅拌，室温下将5μg rgD2l/剂量培养1小时。用氯化钠溶液（5M，PH6.5±0.5）和注射用水调节其体积至70μl。然后加入QS21（10μg/剂量）。保持PH值为6.5±0.5，氯化钠的最后浓度为0.15M。
＊rgD2l/3D-MPL/QS21
在搅拌和室温下使5μg rgD2t培养1小时。然后加入3D-MPL（25μg/剂量）的水悬浮液。通过添加QS21（10μg/剂量）的水溶液使最后的体积为70μl，并保持PH值为6.5±0.5，氯化钠浓度为0.15M。
1.2免疫接种
用35μl/爪垫的制剂注射于小鼠的后爪垫中。因此，这样每个小鼠接受了70μl。第零天和第14天进行免疫接种，在第21天将小鼠杀死。
1.3干扰素γ测定
在体外使用10、1、0.1、1、0μg/ml的rgD2l来刺激经免疫的小鼠的腘淋巴结细胞。在园底96孔微量滴定（microtiter）极中作用2×105应答细胞和2×105辐照（3000rad）过的同源的首次用来用实验的脾细胞备好一式三份的培养物（200μl体积）。培养介质是含10%胎儿腓血清的RPMI1640。采集并汇集每一种复试验用的100μl培养介质的等分试样以作IFN-γ测定。培养物在72小时时分析测定。对于所有测定，均包括使用5μg/ml的ConA（Boehringer Mannheim）对照组。各组均呈阳性。
使用Holland        Biotechnology（Gibco分部）生产的商用ELISA测定仪测定IFN-γ的分泌。对由一式三份的试样容器得到的100μl汇集的上层清液进行测试。
对所有三种制剂组（见表）观察其以50Pg/μl为实验基准IFN-γ的分泌作用。此外，测得QS21和3D-MPL间的协同效应。虽然每种佐剂自身诱导细胞能分泌IFN-γ对rgD2t作出应答，但它们的组合诱导的应答则比单独每一个应答之和的两倍还多。
1.4结果
Figure 93107990X_IMG1
IFN-γ以pg/ml表示。
该表清楚地表明了组合的疫苗以协同方式诱导IFN-γ的分泌。
2.0    3D-MPL和QS21对CTLs诱导的协同作用
为了测试在基于3D    MPL和QS21的佐剂制剂中的RTS，S颗粒诱导CTLs的能力，对几组B10、BR小鼠进行免疫接种，并在体外刺激它们的脾脏细胞，并对以CS蛋白表示的L细胞的细胞毒性实验进行测试。
2.1RTS，S颗粒的制剂
以三种不同的组成来配制RTS，S颗粒：
1.含QS21（10μg）和3D-MPL（25μg）的RTS，S颗粒（10μg）;
2.含QS21（10μg）的RTS，S颗粒（10μg）;
3.含3DK-MPL（25μg）的RTS，S颗粒（10μg）;
制剂按下述过程制备：
RTS，S/3D        MPL
在室温搅拌下培养10μg的RTS，S颗粒/剂量1小时，然后使其与3D    MPL水悬浮液（25μg/剂量）混合。用注射用水和氯化钠溶液（5N，PH6.5±0.5）调节体积至70μl/剂量，NaCl的最后浓度为0.15M（PH保持在6.5±0.5）。
RTS，S/QS21
在室温搅拌下培养10μg的RTS，S颗粒/剂量1小时。用注射用水和氯化钠溶液（5N，PH6.5±0.5）调节体积，并用QS21的水溶液（10μg/剂量）使最后的体积为70μl/剂量。PH保持在6.5±0.5，氯化钠的最后浓度为0.15M。
RTS，S/3D        MPL/QS21
在室温搅拌下培养10μg的RTS，S颗粒/剂量1小时，然后使其与3D    MPL（水悬浮液（25μg/剂量）混合。然后用注射用水和氯化钠溶液（5N    PH6.5±0.5）调节其体积。最好的体积通过添加QS21的水溶液（10μg/剂量）来完成。PH值保持6.5±0.5，氯化钠的最后浓度为0.15M。
2.2用RTS，S颗粒对小鼠进行免疫接种
从IFFA CREDO（法国）购买4-6周的B10.BR（H-2K）种雌性小鼠。3个为一组对其进行免疫接种，即在每个后肢内爪垫内注射35μl的抗原制剂。两周后，用第二份相同剂量的抗原注射使小鼠加强接种。
2.3对于抗CS    CTL进行体外刺激
被加强后两周，采集脾脏细胞，并用经P.falciparum环子孢子蛋白基因（7G8克隆）转染的同源的成纤维细胞进行体外刺激。这些CS转染子细胞在Kumar，S.等（1988）的文章中有述，Nature    334∶258-260。
在本领域普通技术人员公知的条件下，以补充有10%的热失活的胎儿腓血清的常用的添加剂的RPMI1640介质中确立培养物。
在105CS转染子/ml存在下，以106细胞/ml的浓度对应答细胞进行培养。为了防止CS转染子细胞的再育，用2×104rad的剂量对其进行辐照。在第3天和第6天通过替换1/2的培养介质培育培养物，在第七天测试其细胞溶解活性。
2.4对于抗CS    CTL的细胞毒性实验
对应答细胞培养物进行采集、洗涤，并在200μl介质中在V型底96孔板中使其与常数为2000的靶细胞以100∶1～0.3∶1的比例进行混合。
靶细胞是同源的成纤维细胞，它已用51Cr进行标记。
使用两种不同类型的靶细胞：
1.L细胞
2.CS转染的L细胞
它们在下述文献中有述：Kumar，S等（1988），Nature    334∶258-260。
被化验物在37℃下进行培养6小时。测定经靶细胞的溶胞而释放进入上层清液的放射性量。
以%特异性溶胞来表示细胞溶解活性：结果：
Figure 93107990X_IMG2
用QS21和3D-MPL作佐剂的RTS，S（制剂＃1）对B10.BR小鼠的免疫接种在脾中诱导了对于RTS，S的环子孢子组分特异的高含量的CTL。用QS21作佐剂的RTS，S颗粒（制剂＃2）的免疫接种也能诱导脾中的CTL，但仅仅是制剂＃1所给出的含量的约1/30。用3D-MPL作佐剂的RTS，S（制剂＃3）则不能诱导CTL。
由于用于本实验的靶细胞并不表示MHCⅡ级分子，效应物细胞可被假定为CD8+，Ⅰ级限制的CTL。
3.其它制剂
乙型肝炎表面抗原，明矾3D-MPL和QS21。
乙型肝炎表面抗原（HBsAg）的制备已有许多论述，如可参见Harford等，Develop    Biol    Standard    54    P        125（1983），Gregg等，Biotechnology    5    p479（1987），EP-A-0226846和EP-A-299108，它们均被在此引用作为参考。
3D-MPL由Ribi    Immunochem得到，QS21由Cambridge    Biotech得到，氢氧化铝由Superfos（Alhydrogel）得到。
制备多种不同的制剂用以研究对小鼠的细胞介导的免疫性及对猕猴进行研究。
3.1在磷酸盐缓冲溶液（PH6.8）中制备制剂1，
每60μl剂量的制剂包含：
20μg        HBsAg
30μg Al（OH）3
30μg        3D-MPL
10μg        QS21
10mM PO4 3-
0.15M        NaCl
制剂按下述过程制备，在室温及温和的振荡下使20μg HBsAg剂量与Al（OH）3培养1小时。随后加入3D-MPL和水悬浮液，通过添加QS21、磷酸盐缓冲液和氯化钠完成制剂制备，并在室温下培养1小时。最后的制剂的PH值在6.5-7.0之间，并将其用于小鼠的爪垫研究。
3.2在磷酸盐缓冲溶液（PH6.8）中制备制剂2，每200μl剂量的制剂包含：
1μg        HBsAg
100μg Al（OH）3
50μg        3D-MPL
20μg        QS21
10mM PO4 3-
0.15M        NaCl
制剂按下述过程制备。在室温及温和的振荡下使用HBsAg与Al（OH）3一起培养1小时。通过添加Al（OH）3、3D-MPL的水悬浮液及QS21，用磷酸盐缓冲液和氯化钠溶液完成制剂的制备，并再培养30分钟。制剂的PH值保持在6.5-7.0之间，它用于小鼠的体液免疫性研究。
3.3用类似的方式在磷酸盐缓冲液（PH6.5-7.0）中制备制剂3，每1ml剂量中包含：
10μg            HBsAg
500μg Al（OH）3
50μg        3D-MPL
10μg        QS21
制剂被用于猴的研究。
4结论
两种佐剂QS21和3D-MPL与重组体颗粒性抗原RTS，S的组合能有效地诱导脾脏中CS蛋白特异的CTL。QS21自己增强了CTL的诱导，而3D-MPL则不能诱导。这种组合能以协同的方式起作用，由于其作用大于每种佐剂单独效用之和。两种佐剂对CTL诱导的协同性是一个令人惊奇的实验结果，该结果表明了QS21和3D-MPL对T细胞的诱导具有协同作用，所述T细胞能够分泌IFN-γ以应答对用可溶性重组体蛋白gD2t的刺激。该发现对于使用重组体分子用于诱导CTL介导的免疫的疫苗具有重要意义。这是因为两种佐剂QS21和3D-MPL的组合能够克服基于重组体蛋白的疫苗的严重的局限性，并较之现有的疫苗能在更宽范围内诱导免疫应答。
小鼠细胞介导的免疫原性数据表明，基于QS21的rgD2t制剂诱导了显著的协同性THI型T细胞应答（IFN-γ分泌）。
这种THI型T细胞已表明与诱导小鼠延迟型过敏性应答有关。我们自己的预防HSV疾病的数据表明，中和抗体值和抗原特异性DTH应答的伴随诱导对于抵抗单纯疱疹疾病提供最好的防护。
总之，这些数据向我们表明，rgD2t的QS21制剂可以有效地诱导一种保护性应答以抵抗HSV疾病。所提供的数据还表明了3D单磷酰类酯A（3D Monophosphoryl Lipid A）和QS21对于诱导IFN-γ分泌抗原特异性T细胞具有意外的协同作用。这种协同性可以表现为增强诱导保护性应答以抵抗HSV疾病的能力，而且这些制剂的确可有效地防护抵抗天竺鼠的疾病。

Claims (12)

1、一种疫苗组合物，它包含一种抗原和/或抗原组合物、QS21的3De-O-酰化的单磷酰类脂A(3D-MPL)。
2、一种按权利要求1的疫苗，其中QS21与3D-MPL的比值为1∶10-10∶1。
3、一种权利要求1或2所要求保护的疫苗组合物，能够在哺乳动物中对抗原或抗原组合物引起细胞溶解的T细胞应答。
4、一种按权利要求1-3任一项所要求保护的疫苗组合物，能够刺激干扰素γ生成。
5、一种按权利要求1-4任一项所要求保护的疫苗组合物，其中QS21与3D-MPL的比值为1∶1～1∶2.5。
6、一种按以上权利要求的疫苗组合物，包含一种抗原或抗原组合物，它们得自于下述中的任一种：人体免疫缺乏病毒、猫免疫缺乏病毒、单纯疱疹病毒1型、单纯疱疹病毒2型、人体细胞肥大病毒、肝炎A、B、C或E、呼吸全胞体病毒、人体乳头状瘤病毒、流感病毒、沙门氏菌、奈瑟菌属、疏螺旋体属、衣原体属、博代杆菌属、疟原虫属或弓浆虫属。
7、一种按权利要求1-5中任一项所要求保护的疫苗，其中抗原为一种肿瘤抗原。
8、权利要求1-5任一项所限定的组合物的用途，用于制造一种用于预防治疗病毒、细菌或寄生虫感染的疫苗。
9、权利要求1-5任一项所限定的组合物的用途，用于制造一种用于免疫疗法治疗病毒、细菌、寄生虫感染或癌症的疫苗。
10、一种治疗患有或可能被一种病原感染的哺乳动物的方法，该方法包括施用安全且有效量的权利要求1-5任一项的组合物。
11、一种治疗患有癌症的哺乳动物的方法，该方法包括施用安全且有效量的权利要求1-5任一项的组合物。
12、一种制备权利要求1-5的疫苗组合物的方法，该方法包括使QS21和3D-MPL与一种抗原或抗原组合物混合。
CN93107990A 1992-06-25 1993-06-24 疫苗 Expired - Lifetime CN1122530C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9213559.9 1992-06-25
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
GB929226283A GB9226283D0 (en) 1992-12-17 1992-12-17 Vaccines
GB9226283.1 1992-12-17
GB9304056.6 1993-03-01
GB939304056A GB9304056D0 (en) 1993-03-01 1993-03-01 Vaccines

Publications (2)

Publication Number Publication Date
CN1086142A true CN1086142A (zh) 1994-05-04
CN1122530C CN1122530C (zh) 2003-10-01

Family

ID=27266263

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93107990A Expired - Lifetime CN1122530C (zh) 1992-06-25 1993-06-24 疫苗

Country Status (30)

Country Link
US (2) US5750110A (zh)
EP (2) EP0671948B1 (zh)
JP (1) JP3755890B2 (zh)
KR (1) KR100278157B1 (zh)
CN (1) CN1122530C (zh)
AP (1) AP408A (zh)
AT (2) ATE188613T1 (zh)
AU (1) AU661404B2 (zh)
CA (1) CA2138997C (zh)
CZ (1) CZ282235B6 (zh)
DE (2) DE69327599T2 (zh)
DK (2) DK0671948T3 (zh)
ES (2) ES2108278T3 (zh)
FI (1) FI109767B (zh)
GR (2) GR3025184T3 (zh)
HU (1) HU219808B (zh)
IL (1) IL106109A (zh)
MA (1) MA22911A1 (zh)
MX (1) MX9303773A (zh)
MY (1) MY109278A (zh)
NO (1) NO317546B1 (zh)
NZ (1) NZ253137A (zh)
PL (1) PL170980B1 (zh)
PT (1) PT761231E (zh)
RU (1) RU2118164C1 (zh)
SG (2) SG90042A1 (zh)
SI (1) SI9300335B (zh)
SK (1) SK279188B6 (zh)
UA (1) UA40597C2 (zh)
WO (1) WO1994000153A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374151C (zh) * 1997-12-02 2008-03-12 神经实验室有限公司 产生免疫的药物组合物及其在制备预防和治疗致淀粉样病的药物中的用途
CN103405764A (zh) * 2005-12-13 2013-11-27 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物

Families Citing this family (482)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
BR9809149A (pt) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
AU3968599A (en) * 1998-04-29 1999-11-16 American Cyanamid Company Vaccines containing recombinant pilin against Neisseria Gonorrhoeae or Neisseria Meningitidis
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
JP2002522451A (ja) * 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
AU5565599A (en) 1998-08-14 2000-03-06 Dante J. Marciani Chemically modified saponins and the use thereof as adjuvants
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP1137777B1 (en) 1998-12-08 2011-10-05 GlaxoSmithKline Biologicals s.a. Novel compounds derived from neisseria meningitidis
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
PT1163343E (pt) 1999-03-12 2010-02-23 Glaxosmithkline Biolog Sa Polipéptidos antigénicos de neisseria meningitidis, polinucleótidos e anticorpos protectores correspondentes
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
HK1049848A1 (zh) 1999-04-02 2003-05-30 科里克萨有限公司 用於治療和診斷肺癌的化合物和方法
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2001054719A2 (en) * 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Vaccine for the prophylactic or therapeutic immunization against hiv
DE60143425D1 (de) 2000-02-23 2010-12-23 Smithkline Beecham Biolog Neue verbindungen
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1961819A3 (en) 2000-06-28 2008-11-12 Corixa Corporation Composition and methods for the therapy and diagnosis of lung cancer
OA12302A (en) 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EP1417236A4 (en) 2001-07-10 2010-03-17 Corixa Corp COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2860702C (en) 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA04010255A (es) 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
DK2011510T3 (da) * 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT1581812E (pt) 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2005021033A2 (en) 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccine
ATE474595T1 (de) 2003-10-02 2010-08-15 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
EP2561884B1 (en) 2004-02-05 2017-01-04 The Ohio State University Research Foundation Chimeric VEGF peptides
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
EP1755666B1 (en) 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Vaccine compositions comprising virosomes and a saponin adjuvant
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
KR20130110233A (ko) 2005-04-29 2013-10-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
JP5222134B2 (ja) 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US7968694B2 (en) 2005-07-01 2011-06-28 Forsyth Dental Infirmary For Children Tuberculosis antigen detection assays and vaccines
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
BRPI0618254A2 (pt) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP2009522011A (ja) 2005-12-30 2009-06-11 Ｔｔｉ・エルビュー株式会社 活性物質を生体界面に送達するイオントフォレーシスシステム、装置及び方法
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
SG10201600336RA (en) 2006-01-17 2016-02-26 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP1998802A2 (en) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20070243199A1 (en) 2006-03-30 2007-10-18 Embrex, Inc. Methods and compositions for vaccination of poultry
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2390360A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IDO1 gene
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
ES2525732T3 (es) 2006-07-18 2014-12-29 Glaxosmithkline Biologicals S.A. Vacunas contra el paludismo
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008091398A2 (en) * 2006-08-31 2008-07-31 Baylor Research Institute Jc virus vaccine
EP2491947A3 (en) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccine
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2008135514A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001284A (es) * 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
WO2009020553A2 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
ES2658347T3 (es) 2007-08-13 2018-03-09 Glaxosmithkline Biologicals Sa Vacunas
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
CA2699856C (en) 2007-09-17 2019-08-20 Oncomethylome Sciences Sa Improved methylation detection
EP2045263A1 (en) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2722056A1 (en) 2007-12-03 2014-04-23 President and Fellows of Harvard College CT062, a Chlamydia antigen
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
US9527906B2 (en) 2008-04-18 2016-12-27 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
CA2725329C (en) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2009270399A1 (en) * 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Chimeric respiratory syncytial virus polypeptide antigens
LT2315597T (lt) 2008-07-25 2018-02-12 Glaxosmithkline Biologicals S.A. Naujos kompozicijos ir būdai
PT2315834T (pt) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CN102239253A (zh) 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 谷氨酰tRNA合成酶（GtS）片段
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
CA2755734A1 (en) 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
EP2413950A4 (en) 2009-04-03 2013-05-01 Univ Washington ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
BRPI1014031A2 (pt) 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
IN2012DN00446A (zh) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2771863A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
PE20121544A1 (es) 2009-09-03 2012-12-02 Pfizer Vaccines Llc Vacuna de pcsk9
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
NZ629256A (en) 2009-12-22 2016-02-26 Celldex Therapeutics Inc Vaccine compositions
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
WO2011150258A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
EP3170508B1 (en) 2010-06-04 2019-11-13 Wyeth LLC Vaccine formulations
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EA201390676A1 (ru) 2010-11-08 2013-11-29 Инфекшес Дизиз Рисерч Инститьют Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
ES2716010T3 (es) 2011-03-29 2019-06-07 Uab Research Foundation Métodos y composiciones para la proteína IL-10 de citomegalovirus
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US20150190501A1 (en) 2011-09-12 2015-07-09 Imperial Innovations Limited Methods and compositions for raising an immune response to hiv
CN103930436A (zh) 2011-09-14 2014-07-16 诺华股份有限公司 大肠杆菌疫苗组合
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
US10752676B2 (en) 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
KR20140101835A (ko) 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
EP2833900B1 (en) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN104321078A (zh) 2012-04-26 2015-01-28 诺华股份有限公司 抗原和抗原组合
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CA2871711A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
PT2879701T (pt) 2012-08-03 2024-02-12 Access To Advanced Health Inst Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
SMT201800011T1 (it) 2012-11-30 2018-05-02 Glaxosmithkline Biologicals Sa Antigeni e combinazioni di antigeni di pseudomonas
ES2939307T3 (es) 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica
US9909114B2 (en) 2013-03-28 2018-03-06 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
JP2016520077A (ja) 2013-05-15 2016-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｅ１ｅ２ｈｃｖワクチン及び使用方法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CA2918644A1 (en) 2013-06-26 2014-12-31 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2015103104A1 (en) 2014-01-06 2015-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated salmonella enterica
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3206112A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
KR102242875B1 (ko) * 2014-03-25 2021-04-20 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 리프리젠티드 바이 더 세크리터리 오브 더 아미 모노포스포릴 지질 a (mpla)-함유 리포솜 조성물 및 사포닌을 포함하는 무독성 아주반트 제제
WO2015197737A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016070178A1 (en) 2014-11-02 2016-05-06 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
EP3229833A1 (en) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
EP3258961A4 (en) 2015-02-20 2018-08-22 Board of Regents, The University of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
JP2018507860A (ja) * 2015-02-26 2018-03-22 ザヴァックス ジェネティクス ワクチン カンパニー リミテッドＴｈｅｖａｘ Ｇｅｎｅｔｉｃｓ Ｖａｃｃｉｎｅ Ｃｏ．， Ｌｔｄ． 抗原特異的ｔ細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3273989B1 (en) 2015-03-26 2023-12-27 Gpn Vaccines Pty Ltd Streptococcal vaccine
EP3302544A4 (en) 2015-05-26 2019-01-09 Ohio State Innovation Foundation NANOPARTICLE-BASED VACCINE STRATEGY AGAINST SWINE INFLUENZA VIRUS
EP3302536A1 (en) 2015-06-03 2018-04-11 Affiris AG Il-23-p19 vaccines
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
EP3325008B1 (en) 2015-07-21 2025-09-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3341017B1 (en) 2015-08-25 2024-10-16 Babita Agrawal Immunomodulatory compositions comprising caulobacter crescentus and use thereof
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
EP4491735A3 (en) 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3733201A1 (en) 2016-01-19 2020-11-04 Pfizer Inc Cancer vaccines
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
US20170260286A1 (en) 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
CR20180445A (es) 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3057778A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Biologicals Sa Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
EP3615005B1 (en) 2017-04-28 2025-07-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Compositions and methods for vaccine delivery
CA3072018A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
AU2018331874B2 (en) 2017-09-13 2022-06-02 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2019079594A1 (en) 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
BR112020024285A2 (pt) 2018-06-12 2021-03-02 Glaxosmithkline Biologicals S.A. polinucleotídeos e polipeptídeos de adenovírus
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN112912097A (zh) 2018-08-23 2021-06-04 葛兰素史密丝克莱恩生物有限公司 免疫原性蛋白和组合物
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
AU2018449744A1 (en) 2018-11-16 2021-05-27 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
EP3890775A1 (en) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020178359A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EA202192392A1 (ru) 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4477230A3 (en) 2019-08-06 2025-05-14 The University of North Carolina at Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用
EP4093873A4 (en) 2020-01-24 2024-07-10 AIM ImmunoTech Inc. Methods, compositions, and vaccines for treating a virus infection
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
AU2021223184C1 (en) 2020-02-23 2025-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021169673A1 (en) 2020-02-26 2021-09-02 Versitech Limited Pd-1-based vaccines against coronavirus infection
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022083768A1 (zh) 2020-10-23 2022-04-28 江苏省疾病预防控制中心(江苏省公共卫生研究院) 免疫原性组合物及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021373358B2 (en) 2020-11-04 2026-01-08 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US20240299510A1 (en) 2020-12-31 2024-09-12 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN119317445A (zh) 2022-05-11 2025-01-14 辉瑞公司 用于生产含有防腐剂的疫苗制剂的方法
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
CN120456919A (zh) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4713008A2 (en) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
WO1989011128A1 (en) * 1988-05-03 1989-11-16 Wang Laboratories, Inc. Microprocessor having external control store
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
EP0614465B1 (en) 1991-11-16 1999-03-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374151C (zh) * 1997-12-02 2008-03-12 神经实验室有限公司 产生免疫的药物组合物及其在制备预防和治疗致淀粉样病的药物中的用途
CN103405764A (zh) * 2005-12-13 2013-11-27 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物

Also Published As

Publication number Publication date
CZ282235B6 (cs) 1997-06-11
GR3032742T3 (en) 2000-06-30
HU9403778D0 (en) 1995-02-28
AP9300541A0 (en) 1993-07-31
ATE188613T1 (de) 2000-01-15
IL106109A (en) 1997-02-18
JP3755890B2 (ja) 2006-03-15
AP408A (en) 1995-09-27
ATE156710T1 (de) 1997-08-15
EP0671948A1 (en) 1995-09-20
FI946064A0 (fi) 1994-12-23
KR950702125A (ko) 1995-06-19
KR100278157B1 (ko) 2001-01-15
EP0671948B1 (en) 1997-08-13
AU661404B2 (en) 1995-07-20
SG90042A1 (en) 2002-07-23
UA40597C2 (uk) 2001-08-15
PL170980B1 (pl) 1997-02-28
ES2143716T3 (es) 2000-05-16
DE69313134D1 (de) 1997-09-18
CZ329694A3 (en) 1995-08-16
CN1122530C (zh) 2003-10-01
CA2138997C (en) 2003-06-03
IL106109A0 (en) 1993-10-20
DE69313134T2 (de) 1998-02-26
SI9300335B (sl) 2003-04-30
ES2108278T3 (es) 1997-12-16
AU4326393A (en) 1994-01-24
FI946064L (fi) 1995-02-22
FI109767B (fi) 2002-10-15
HU219808B (hu) 2001-08-28
NO945003D0 (no) 1994-12-23
JPH07508512A (ja) 1995-09-21
GR3025184T3 (en) 1998-02-27
MA22911A1 (fr) 1993-12-31
HK1010097A1 (zh) 1999-06-11
DE69327599T2 (de) 2000-08-10
US7147862B1 (en) 2006-12-12
EP0761231B1 (en) 2000-01-12
DK0761231T3 (da) 2000-05-08
RU94046232A (ru) 1996-10-10
DE69327599D1 (de) 2000-02-17
EP0761231A1 (en) 1997-03-12
SK279188B6 (sk) 1998-07-08
WO1994000153A1 (en) 1994-01-06
NO945003L (no) 1994-12-23
SG49909A1 (en) 1998-06-15
NZ253137A (en) 1996-08-27
DK0671948T3 (da) 1997-09-01
CA2138997A1 (en) 1994-01-06
US5750110A (en) 1998-05-12
RU2118164C1 (ru) 1998-08-27
SK159294A3 (en) 1995-08-09
SI9300335A (sl) 1993-12-31
HK1022074A1 (zh) 2000-07-21
MY109278A (en) 1996-12-31
PT761231E (pt) 2000-06-30
NO317546B1 (no) 2004-11-15
HUT71208A (en) 1995-11-28
MX9303773A (es) 1994-05-31

Similar Documents

Publication Publication Date Title
CN1086142A (zh) 疫苗
CN1087176C (zh) 含有3－o脱酰基单磷酰脂a的疫苗制剂
CN1289065C (zh) 含有皂苷和固醇的疫苗
JPH09506887A (ja) ワクチン
HK1022074B (zh) 含有佐剂的疫苗合剂
HK1010097B (zh) 含有辅药的疫苗合剂
HK1023499B (zh) 含有3-0脱酰单磷酰基类酯a的疫苗组合物
HK1011930B (zh) 含有3-o脱酰单磷酰基脂质a的疫苗组成

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20130624

Granted publication date: 20031001